GammaDelta Therapeutics initiates first-in-human phase 1 trial of GDX012 for the treatment of acute myeloid leukemia

GammaDelta Therapeutics Ltd., a biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer, today announced that it has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukemia.

Generated by Feedzy